Abstract

Beginning with this issue of Pharma Horizon, we are launching a new editorial section called “Panel Discussion” which will treat different and relevant topics for companies involved in the pharmaceutical manufacturing value chain.

This will be done by involving some of the major industry players, called to express their opinion on some food for thought proposed by our editorial team.

In this issue we want to offer our readers the point of view of the CROs and CDMOs regarding the state of the art and the future perspectives of this very important segment of the pharmaceutical manufacturing value chain. The following companies have joined the initiative – Cambrex, Fareva, Icrom and Olon – to whom we have asked which are the most promising therapeutic areas for the  CRO/CDMO business development and which are the main trends that will characterize their operations in the future.

The panelists also questioned about the technological level that distinguishes their companies, about which are the main innovations that will have to be updated and be able to address client needs and if these innovations can be found internally or must be acquired from outside, maybe by M&A deals.

Finally, we have asked them about the importance and implementation of the Internet of Things in the supply chain and the importance of integrated outsourcing.

Here are their opinions. Enjoy the reading.

TKS Publisher Editorial Team

THE FUTURE OF CMOS TO THE PHARMACEUTICAL INDUSTRY

Simon Edwards - VP Sales & Business Development at Cambrex

Contract manufacturing organisations (CMOs) have seen some tumultuous times over the last few decades. However, it seems as though small molecule API manufacturers will continue to have an important role in the industry.

Despite the interest and investment we have seen in the biologics market recently which will undoubtedly continue, it is expected that small molecules will remain a core focus for the pharmaceutical industry over the next 5 years, with FDA approvals expected to remain steady at 25-35 NCEs per year. In terms of treatments, oncology will continue to account for a growing number of product approvals (currently around 30% of new small molecule drugs) as well as drugs being developed for orphan indications.

CMOs have had to undergo many changes ... ...